首页> 外文会议>Annual International Conference of the IEEE Engineering in Medicine and Biology Society >Colorimetric determinations of lithium levels in drop-volumes of human plasma for monitoring patients with bipolar mood disorder
【24h】

Colorimetric determinations of lithium levels in drop-volumes of human plasma for monitoring patients with bipolar mood disorder

机译:用于监测双极情绪障碍患者的人血浆液滴液滴锂水平的比色测定

获取原文

摘要

Lithium preparations are considered the most reliable form of mood stabilizing medication for patients with Bipolar disorder. Nevertheless, lithium is a toxic element and its therapeutic range is extremely narrow, with levels of 0.61.0 mEq considered normal, whereas levels above 1.5 mEq are toxic. Thus unfortunately, many patients reach toxic levels that lead to unnecessary complications. It is believed that personal monitoring of blood lithium levels would benefit patients taking lithium medication. Therefore, our aim is to develop a personal lithium blood level analyzer for patients with bipolar mood disorder, and we report here our initial results of a colorimetric-based method used to test drop-volumes of human plasma that had been spiked with lithium. It was possible to validate results with standard flame photometry readings. Applying the Partial Least Squares (PLS) method on preprocessed spectra, therapeutic concentrations of lithium in a single drop can be predicted in a rapid manner, and furthermore, the calibration results were used to select effective wavelengths which were employed as inputs in Multiple Linear Regression (MLR). The simplified algorithms of this would prove useful when developing a personal lithium analyzer. Overall, both calibration methods gave high correlation and small error outputs with a R2= 0.99036 and RMSEC = 0.03778, and R2= 0.994148 and RMSEC= 0.0294404, for PLS and MLR methods, respectively. The results show that the spectrophotometric determination of blood lithium levels can be extended beyond laboratory applications and indicate the capability of this testing principle to be employed in a personal monitoring device. Future work will now focus on the technical development of a miniaturized system for measurement of lithium levels in blood with an acceptable level of accuracy and sensitivity.
机译:锂制剂被认为是双相障碍患者的最可靠的情绪稳定药物。然而,锂是一种有毒元素,其治疗范围极为窄,水平为0.61.0 meq认为正常,而含量超过1.5meq的水平是有毒的。因此,很遗憾,许多患者达到毒性水平,导致不必要的并发症。据信,个人监测血液锂水平将使患者受益于服用锂药物。因此,我们的宗旨是为双极情绪障碍的患者开发个人锂血液水平分析仪,我们在此报告了我们的初始结果,用于测试用锂掺入的人血浆的滴产量的基于比色方法。可以使用标准火焰光度测量读数验证结果。在预处理的光谱上施加部分最小二乘(PLS)方法,可以以快速的方式预测单个液滴中锂的治疗浓度,此外,校准结果用于选择有效波长,该波长在多元线性回归中使用作为输入的有效波长(MLR)。在开发个人锂分析仪时,这的简化算法将证明是有用的。总的来说,两个校准方法都具有高相关和小错误输出,R2 = 0.99036和RMSEC = 0.03778,以及PLS和MLR方法的R2 = 0.994148和RMSEC = 0.0294404。结果表明,分光光度法测定血液锂水平可以延长实验室应用,并指出该测试原理在个人监测装置中使用的能力。未来的工作现在将专注于小型化系统的技术开发,用于测量血液中锂水平,具有可接受的准确性和敏感性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号